Abstract:Diffuse low-grade gliomas account for approximately 20% of all primary brain tumors, they arise from glial cells and show infiltrative growth without histological features of malignancy. Mutations of the IDH1 and IDH2 genes constitute a reliable molecular signature of low-grade gliomas and are the earliest driver mutations occurring during gliomagenesis, representing a relevant biomarker with diagnostic, prognostic, and predictive value. IDH mutations induce a neomorphic enzyme that converts α-ketoglutarate to the oncometabolite D-2-hydroxyglutarate, which leads to widespread effects on cellular epigenetics and metabolism. Currently, there are no approved molecularly targeted therapies and the standard treatment for low-grade gliomas consists of radiation therapy and chemotherapy, with rising concern about treatment-related toxicities. Targeting D-2-hydroxyglutarate is considered a novel attractive therapeutic approach for low-grade gliomas and the insights from clinical trials suggest that mutant-selective IDH inhibitors are the ideal candidates, with a favorable benefit/risk ratio. A pivotal question is whether blocking IDH neomorphic activity may activate alternative oncogenetic pathways, inducing acquired resistance to IDH inhibitors. Based on this rationale, combination therapies to enhance the antitumor activity of IDH inhibitors and approaches aimed at exploiting, rather than inhibiting, the metabolism of IDH-mutant cancer cells, such as poly (adenosine 5′-diphosphate-ribose) polymerase inhibitors, are emerging from preclinical research and clinical trials. In this review, we discuss the pivotal role of IDH mutations in gliomagenesis and the complex interactions between the genomic and epigenetic landscapes, providing an overview of how, in the last decade, therapeutic approaches for low-grade gliomas have evolved.

IDH Inhibitors and Beyond: The Cornerstone of Targeted Glioma Treatment

Molecular biology and novel therapeutics for IDH mutant gliomas: The new era of IDH inhibitors

IDH inhibition in gliomas: from preclinical models to clinical trials

Therapeutic inhibition of isocitrate dehydrogenase mutations in glioma and cholangiocarcinoma: new insights and promises-a narrative review

IDH mutation in glioma: molecular mechanisms and potential therapeutic targets

Isocitrate Dehydrogenase Inhibitors in Glioma: From Bench to Bedside

Advances in the treatment of IDH-mutant gliomas

Multidisciplinary Management of Isocitrate Dehydrogenase–Mutated Gliomas in a Contemporary Molecularly Defined Era

IDH Mutations in Glioma: Molecular, Cellular, Diagnostic, and Clinical Implications

Targeting IDH-Mutant Glioma

Treatment of IDH-mutant glioma in the INDIGO era

To be Wild or Mutant: Role of Isocitrate Dehydrogenase 1 (IDH1) and 2-Hydroxy Glutarate (2-HG) in Gliomagenesis and Treatment Outcome in Glioma

Systematic Review of Epigenetic Therapies for Treatment of IDH-mutant Glioma

Glioma targeted therapy: insight into future of molecular approaches

Treatment Options for IDH-Mutant Malignant Gliomas

Implications of IDH mutations on immunotherapeutic strategies for malignant glioma.

The Role of Mutant IDH Inhibitors in the Treatment of Glioma

Advances in the Immunotherapeutic Potential of Isocitrate Dehydrogenase Mutations in Glioma

Inhibition of 2-hydroxyglutarate elicits metabolic reprogramming and mutant IDH1 glioma immunity in mice

Small Molecule Inhibitors in Adult High-Grade Glioma: From the Past to the Future

IDH1/2 Mutations Target a Key Hallmark of Cancer by Deregulating Cellular Metabolism in Glioma